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Summary The Qualitator is a daily diary card to measure Quality of Life, developed for use in chemotherapy
trials for patients with advanced breast cancer. In a trial at King's College Hospital, 29 patients completed the
Qualitator and their scores were compared with scores in the Linear Analogue Self-Assessment and Nottin-
gham Health Profile taken four-weekly. In a separate study at Guy's Hospital, 31 patients completed the diary.
The Qualitator offers accurate prognostic data regarding subsequent UICC response and survival and is simple
to use.
The use of combination cytotoxic chemotherapy as palliation
for patients with advanced breast cancer became established
in the late 1960s (Cooper et al., 1969). Few trials show a
survival advantage for a particular regimen and only recently
has an overall improvement in survival been associated with
treatments giving higher response rates (A'Hern et al., 1988).
Although the aim of treatment is to improve the Quality of
Life (QoL) of the patient, regimens are still compared on the
basis of their response rate in patients where such measure-
ments can be made. Side effects of chemotherapy such as
alopecia, vomiting and lethargy are assumed to affect the
QoL of the patients, but their objective measurement is a
secondary aspect in most trials and subjective, patient
derived, measurements are seldom made.
The simple technique of QoL measurement recording the
patients' subjective symptoms using visual analogue scales
was adapted for use in breast cancer patients by Priestman
and Baum (1976). Since then, QoL measurement in cancer
patients has been advocated widely (Maguire & Selby, 1989).
However, in 1986, Macaulay and Smith reported that in a
review of over 230 advanced breast cancer trials, in only two
had overall QoL been measured. They added that assessment
of the value of particular treatments should not rest upon
response rate alone (Macaulay & Smith, 1986). So it is
disappointing that during 1991, 15 years after Priestman and
Baum's paper was written, of 48 studies of chemotherapy in
advanced breast cancer listed in the index Medicus, we found
only one which included QoL measurement. Many clinicians
still prefer to rely upon their clinical judgement, although
Slevin et al. found poor correlation between QoL measured
by doctor and by patient (Slevin et al., 1988). One problem
may have been the QoL instruments on offer. Well-validated
instruments did not include items about vomiting, nausea or
hair loss and none was specific to breast cancer or
chemotherapy. Moreover, QoL measurement is labour-
intensive. We therefore addressed these problems.
In QoL measurement, a gold standard does not exist, and
according to Bergner, is not desirable (Bergner, 1984).
Instruments fall into two broad categories: multidimensional,
designed to measure specific aspects of disease or treatment,
and global, which give a single score for as broad a represen-
tation of QoL as possible. The former approach was chosen,
to complement existing instruments, with weighting provided
by allowing the patient to choose the items of relevance to
her. To take account of the fluctuations which may be
expected to occur in patients on chemotherapy, a diary for-
mat was adopted. Guidelines proposed in 1986 by Guyatt et
al. (1986) were followed. A six stage process comprises item
selection, item reduction, format design, pretesting, construct
and test-retest reliability and finally validation. Items were
amassed and distilled from all the QoL measures then
available and others were added after consultation with a
panel which included a psychologist, a surgeon, a GP and a
nurse counsellor. The validation of the 'King's Diary' in it
preliminary format was undertaken by Ebbs et al. during a
trial comparing Epirubicin in two different doses and
administration systems, in which 39 patients completed the
initial form of the diary during their treatment (Ebbs et al.,
1989). This development process resulted in the 'Qualitator'
and has been described previously (Fraser et al., 1990).
Validation has continued in two separate trials, described
below.
To test the ability of the Qualitator to measure what it is
purporting to measure, it is necessary to consider what is
known so far about QoL in advanced breast cancer patients,
and in cancer patients in general. Baum et al. reported that a
response to chemotherapy improved QoL scores, especially
for pain and insomnia (Baum et al., 1980); Ebbs et al.
reported that good pre-treatment QoL scores were associated
with a subsequent response (Ebbs et al., 1988). A relationship
between poor QoL and poor survival was reported by Morris
and Sherwood in a study of terminally ill patients (Morris &
Sherwood, 1987). Later, Addington-Hall et al. used the
Spitzer QoL Index to predict survival in 230 terminal
patients (Addington-Hall et al., 1990).
Patients and methods
Patients
Data were collected from two different studies, each with two
arms. In the first, 40 patients with advanced breast cancer
attending King's College Hospital and the William Harvey
Hospital, Ashford, Kent were randomised to receive the stan-
dard 28 day cycle of CMF (Bonadonna et al., 1983) or weekly
Epirubicin 20 mg, for 6 months or until treatment failure
between October 1988 and March 1990. The median age was
Correspondence: S.C.A. Fraser, Department of Surgery, Kings Col-
lege Hospital, Denmark Hill, London SE5 9RS, UK.
Received 14 March, 1992; and in revised form 17 August 1992.
Br. J. Cancer (1993), 67, 341-346 '." Macmillan Press Ltd., 1993342 S.C.A.FRASER et al.
56 years (range 26-84). The baseline Qualitator was completed
by 29 patients (Median age 57 years, range 26-77) who also
completed baseline measure-ments in two well validated QoL
measures, the Nottingham Health Profile (NHP) (Hunt et al.,
1985) and the Linear Analogue Self-Assessment (LASA)
(Priestman & Baum, 1976). The NHP was chosen as a well
validated general measure of QoL and the LASA because it is
an instrument which has been used and validated extensively
in breast cancer trials (Boyd et al., 1988). QoL measurement
was continued for 6 months or until treatment failure.
In the second study, at Guy's Hospital, 39 patients were
randomised to receive doxorubicin 25 mgm-2 weekly or
75 mgm-2 three-weekly to examine the influence of treat-
ment schedule on response, survival and quality of life.
Thirty one patients completed the diary in its preliminary
format between 1986 and 1987, at the commencement of 12
weeks of therapy (Richards et al., 1992) and continued until
treatment was complete unless disease had progressed first.
Their median age was 54 years (32-74). Data from 60
patients were therefore available for analysis.
Administration andscoring ofQoL measures
In each study, QoL instruments were explained to patients in
person and administered by one principal investigator (SF
and AR). The Qualitator is a daily diary card administered
three-weekly and completed continuously from the first day
of treatment (see Figure 1). From 23 items the patient
chooses one she considers the most important from each of
four domains: (1) symptoms of disease and side effects of
treatment, (2) psychological aspects, (3) personal relation-
ships and (4) physical performance. In addition a weighting
variable is chosen from any domain. Daily thereafter, a score
from 1-4 is given to the five chosen items, corresponding to
the severity with which each item is perceived: 'Not at all', 'A
Little', 'Somewhat', 'Very Much'. The opportunity to change
items occurs every three weeks, when a new card is
exchanged for the old one. This period was chosen to suit the
regimens used in the initial study (Ebb et al., 1988) and was
kept for subsequent studies. Each patient's aggregated daily
score is added to obtain a weekly total in the range 35-140.
In both studies, patient groups (and other QoL measures in
the King's study) were compared using a mean diary score
taken from the completed weeks during each successive four
week period. This allowed inclusion of all the available data,
but allowed for any missing weeks. Isolated missing days
were given the mean score for the other days that week.
In the King's study the NHP and LASA were administered
prior to treatment and every 4 weeks thereafter, before the
administration of chemotherapy and the QoL scores were
processed when the study was finished. With all three
instruments, a high score indicates poor QoL. The NHP
gives a weighted score out of 100 for each of six components:
emotional state, energy, pain, physical mobility, sleep and
social factors. Adding the components of the NHP, not part
of its original design, allows a global comparison, giving a
range of 0-600. The LASA consisted of 24 categories, each
scored 0-9, producing a global score range of 0-216. For
comparison between instruments, pre-treatment NHP and
LASA scores were compared with the first week of the
Qualitator and thereafter, the average four-weekly Qualitator
score. Pre-treatment Qualitator scores were not measured, as
this would have necessitated a delay in treatment of one
week. The first week Qualitator score was the closest com-
parison to the pre-treatment NHP and LASA scores.
In both studies, the Mann-Whitney rank test was used to
compare the QoL scores of responders and non-responders 4
weekly and to compare initial and subsequent scores within a
patient group. The difference in change of QoL scores
between responders and non-responders at each 4 weeks of
treatment was performed using the Wilcoxon rank test. Sur-
vival according to the Qualitator scores during the first week
and the first 4 weeks of treatment were calculated using the
Kaplan-Meier life table method (Kaplan & Meier, 1958) and
the log-rank test (Peto et al., 1977).
Patterns of three-weekly item choice were tabulated with-
out statistical analysis. To compare individual items, e.g.
pain, whether chosen in its own domain or as a weighting
item, all patients who ever chose that item during the course
of treatment had that score processed in the same way as the
global scores, giving a rane of 7-28. Patients who never
chose that item were excluded from the analysis, but those
who had not yet chosen the item, or who had stopped
choosing it, were given the score 0 for purposes of non-
parametric statistical comparison, making the range for indi-
vidual items 0-28, the step from 'not yet chosen' or 'no
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Figure 1 The Qualitator.
-QUALITY OF LIFE MEASUREMENT FOR BREAST CANCER 343
longer chosen', to 'chosen, but given minimum score' being
deemed a relevant distinction.
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Results
Compliance
(1) The King's study The NHP and LASA were completed
by all 29 patients who completed the Qualitator, 14 in the
CMF arm and 15 in the Epirubicin arm. Eleven patients did
not complete the Qualitator: three elderly patients were, mis-
takenly, not asked to do so, one patient refused and the rest
either did not start it due to rapid progession of disease, or
were unable to return the completed card on early progres-
sion of disease. The Qualitator was completed for 419 (88%)
out of the total of 474 weeks. The missing weeks were 48
(18%) of 262 and in the CMF arm compared to 7 (3%) of
212 in the Epirubicin arm (X2 = 25.8, P<0.001). One patient
preferred not to indicate the item in each domain which she
had chosen so her data were only allowable for numerical
analysis of the global scores. One patient failed to choose a
weighting question for the fifth domain which was not dis-
covered until the end of the study. Her score was multiplied
by 1.25 in order to allow comparison of her global scores.
There were eight isolated missing days. The NHP and LASA
were completed on 104 of the possible 117 occasions, a
compliance of 89%.
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Figure 2 QoL at the start of treatment for 29 patients who
completed all 3 instruments in the King's study. The LASA,
NHP and Qualitator are scaled to the range 1-10. (R = response,
NR = no response.)
(2) The Guy's study The missing weeks were 13 (11%) of
123 in the weekly treatment arm and 46 (21%) of 220 in the
3-weekly treatment arm (X2 = 5.92, P<0.02). Missing weeks
were incurred most often as a result ofdelayed treatment due
to haematological toxicity, and omission of the diary during
the interim recovery period. There were 15 isolated missing
days.
Response to treatment
In the King's study, 17 (43%) of the 40 patients responded
clinically by UICC criteria. Of the 29 patients who completed
the Qualitator, 15 (52%) responded clinically. In the Guy's
study, 15 (38%) of the original 39 patients responded
clinically, 11 (37%) of the 30 patients who completed the
diary.
QoL at entry to trial
Diary scores for the first week of treatment were taken as the
baseline in both the King's and the Guy's trials. Comparison
was made between the scores of patients who subsequently
had a response to treatment (UICC) and those who did not.
Taken separately, the King's responders had a median of 60,
non responders of 80 (P<0.1). Guy's responders had a
median score of 43, non-responders of 81 (P<0.05). Added
together, responders from both studies had a median of 59
and non-responders 81 (P<0.005). A first-week score of
below 52 gives the highest odds ratio of a response to
treatment, 6.21 (95% c.i. 1.70-22.8). In the both the King's
study and the Guy's study, the first 4 weeks mean diary
scores were significantly better for responders: (King's 56 vs
73, P<0.05; Guy's 55 vs 83, P<0.05). The pre-treatment
NHP and LASA scores in the King's study gave a similar
pattern in predicting responders and non-responders: (LASA
responders 22, non-responders 64, P<0.005; NHP re-
sponders 88, non-responders 162, P<0.1). The initial scores
ofall instruments in the King's study are illustrated in Figure
2, standardised to a common scale of 0-10.
QoL and survival
To assess the relationship between early Qualitator scores
and subsequest survival, the 60 patients from both studies
were divided into high scoring and low scoring groups of
nearly equal size using a threshold score of over 65. Survival
was significantly better for patients with low scores in both
the first week (median survival 57 weeks, 33 weeks; x2= 5.77,
ldf, P<0.02) and the first 4 weeks (median survival 57
weeks, 30 weeks; x2= 14.48, ldf, P<0.001). The survival
curves are illustrated in Figures 3a and b.
In the King's study, an above median Qualitator score at
the start of treatment was of greater prognostic significance
than any other factor (see Table I).
QoL during treatment according to response
The intial difference between the diary scores of responders
and non-responders persisted for 3 months in the King's
study (P = 0.022, P = 0.033, P = 0.010) and 4 months in the
Guy's study (P = 0.021, P = 0.0498, P = 0.028, P = 0.043).
The corresponding differences in global scores for the NHP
and LASA in the King's study were not significant after 1
month.
Comparing patients' first week's Qualitator score with the
corresponding aggregated score for 1, 2 and 3 months, there
were signficant improvements for responders in the King's
study at two months (median 8.55, P<0.05) and 3 months
(median 12.5, P<0.01). There was no differences in the
scores of non-responders. In the same patients, a similar
pattern was observed in the NHP responders at 3 months
(median 67.8, P<0.06) though less so in the LASA (median
1.75, P<0.8). The same trend ofimprovements in QoL score
were not significant in Guy's responders. In order to illus-
trate the weekly trend in QoL scores amongst patients,
Figure 4 shows the mean diary scores in each group
(although non-parametric methods were used for statistical
analysis).
QoL during treatment according to therapy
Comparing the change in Qualitator scores, between the first
week and the subsequent aggregated score for 1, 2 and 3
months, an improvement was recorded in the King's study
for both Epirubicin (median 7.2, P<0.02) and CMF
(median 8.93, P<0.02) patients remaining at 3 months. This
pattern was seen in the NHP score at 3 months for the same
patients on CMF (Median 67.75, P<0.02). In the Guy's
study, patients on the 3 weekly regimen had improved
Qualitator scores at three months (median 9.4, P<0.05).344 S.C.A.FRASER et al.
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Figure 3 a, Survival according to first week Qualitator scores
(>65 n = 31, 65 or less n = 28. Median survival 57 weeks, 33
weeks; x2= 5.77, 1 d.f., P<0.02). b, Survival according to first 4
weeks' Qualitator scores (>65 n = 29, 65 or less n = 31, median
survival 57 weeks, 30 weeks; x2 = 14.48, 1 d.f., P<0.001).
Table I Survival differences according to factors recorded in 29
patients at entry to the King's study
Total x2 p
LASA>45 (median) 14 4.98 0.03
NHP>100 (median) 16 0.70 0.40
Qualitator>65 (median) 15 6.90 0.01
Menopausal 19 0.004 0.95
Site of disease:
Soft tissue 15 3.37 0.07
Nodal 14 0.03 0.86
Bone 13 0.28 0.60
Lung 6 0.13 0.72
Liver 6 4.85 0.03
Analysis ofseparate items and domains
The Qualitator can be sub-analysed in detail but caution has
been exercised to avoid producing spurious results. In Table
II, the total number of 3-weekly item choices in each study
has been compared. In the column marked (%), the figure
represents the total number of 3 weekly choices, including the
weighting choice, made for that item, expressed as a percen-
tage of the figure that would be obtained by distributing all
choices evenly between each item. Domains 1 receives most
of the weighting scores. Pain, tiredness, hair loss, activity and
overall condition are chosen frequently in both studies. One
patient out of the 60 in both studies did not indicate her item
choices and 11 progressed or died on treatment after 3 weeks.
Eight who did not change items from the first week onwards
had a total of 42 opportunities to do so and the remaining 40
who did change had a total of 144 opportunities on which to
No response ........ ..................... ~~~~~~~~~~~~~~~~~~~~~~~~~~....................
...... Response
...
A I 40[
1 2 3 4 5 6 7 8 9 10 11 12
Week oftreatment
Figure 4 Mean Qualitator scores during the first 12 weeks of the
King's (. ) and Guy's ( ) studies, according to UICC res-
ponse.
do so. This opportunity was exercised, respectively, in groups
1, 2, 3, 4 and the weighting group on 48, 46, 21, 41 and 75
occasions.
Analysis of the separate domains 1-4, in the King's study
demonstrated no significant improvement in score for any
patient group in any domain. Differences between the scores
of responders and non-responders are illustrated in Table III.
In the separate items, in the King's study, the only significant
change was that at 3 months the scores for pain had im-
proved for responders (medians 15 to 8.25, P<0.02) but not
for non-responders (15.25 to 16). A similar, though non-
significant trend was observed in the Guy's study.
Discussion
There is no common currency of QoL measurement. In
advanced breast cancer, QoL comprises many facets and as
in other cancers, symptoms change in importance between
patients and over time (Clement Jones, 1985); chemotherapy
adds to this complexity. The recently developed Rotterdam
Symptom Checklist (RSC) is a multidimensional instrument
specifically designed for advanced cancer patients on
chemotherapy which measures many facets but at intermit-
tent timepoints (de Haes et al., 1990). The development of
the Qualitator represents a different response to the same
perceived problem, rather than at attempt to 'reinvent the
wheel' (Aaronson, 1988).
The frequency of diary completion allows few items. Ged-
des et al. used a diary comprising eight obligatory items to
measure QoL in lung cancer patients receiving chemotherapy
(Geddes et al., 1990). Fallowfield pointed out that most QoL
questionnaires have fixed components that might not be
relevant to an individual (Fallowfield, 1990). The Qualitator
only measures five items on any 3 week cycle. However,
permitting the patient to define areas of her life contributing
most to its overall quality was the most novel and important
departure from more traditional instruments. Lumping symp-
toms altogether in a global measurement is regarded by some
as unscientific, askin to 'trying to compare apples and
oranges'. This, however, was the intention: the sum of the
parts was of overall interest. The number of changes of item
made by patients in both studies supports this view.
In spite of small numbers in both the King's and Guy's
studies, the Qualitator can predict patients likely to respond,
supporting the findings of Baum et al. (1980) and Ebbs et al.
(1988). Moreover, patients with high initial scores had poorer
survival, supporting the findings of Morris and Sherwood
(1987) and Addington-Hall et al. (1990).
Compliance for diary completion overall was good in both
the King's study and Guy's study, comparing favourably
with Geddes et al. who obtained 85%. In both studies, moreQUALITY OF LIFE MEASUREMENT FOR BREAST CANCER 345
Table II Relative proportions of items chosen
No
Guy's King's Response Response
Number of
patients 31 28 27 32
Sympt Weight Total % Sympt Weight Total % % %
Pain 27 4 31 187 57 14 71 292 266 267
Breathing 22 1 23 135 9 5 14 58 89 107
Tired 13 13 26 153 24 32 56 230 155 179
Appetite 11 7 18 106 13 5 18 74 44 107
Feel sick 10 5 15 88 19 10 29 119 111 107
Vomiting 4 4 8 47 0 1 1 4 67 36
Bowel upset 7 11 18 106 1 5 6 25 44 71
Hair loss 4 16 20 118 23 20 43 177 155 89
Total 99 61 160 940 146 92 238 979 931 963
Anxiety 23 5 28 115 34 1 35 99 123 100
Depression 28 3 31 127 11 5 16 45 77 87
Sleep 19 3 22 90 74 5 79 224 107 174
Future 17 6 23 94 22 8 30 85 107 112
Life 12 1 13 53 5 0 5 14 61 25
Total 98 18 117 480 146 19 165 467 475 498
Partner 27 1 28 115 41 0 41 116 107 124
Family 39 1 40 164 53 0 53 150 184 149
Friends 6 0 6 25 8 0 8 23 31 12
Sexual 1 0 1 4 1 0 1 3 15 12
Social 23 0 23 107 43 0 43 122 92 112
Total 98 2 101 414 146 0 146 414 429 409
Work 8 1 9 37 14 4 18 51 77 50
Hobbies 2 0 2 8 5 2 7 20 15 0
Activity 40 3 43 176 54 9 63 178 168 149
Overall 25 11 36 148 49 11 60 170 168 124
Self care 23 3 26 107 23 4 27 76 77 149
Total 98 18 116 476 145 30 175 496 505 472
The columns marked (%) indicate the frequency with which an item was chosen expressed as a percentage of the number of times it would
have been chosen if all been chosen with equal frequency (100%).
Table III Median scores and significance levels between responders (R) and non-responders (NR) in the King's
study in separate domains of the NHP, LASA and Qualitator
Month 0 1 2 3 4
response R NR P R NR P R NR P R NR P R NR P
n 15 14 IS 14 14 10 14 7 12 4
NHP
Emotion 21 26 .409 14 23 .103 14 21 .166 14 14 .347 14 45 .129
Energy 0 30 .250 24 24 .828 0 0 .639 0 32 .385 0 69 .041
Mobility 0 20 .033 0 45 .034 0 22 .030 0 11 .425 0 28 .086
Pain 0 10 .178 0 14 .020 0 14 .012 0 11 .079 0 5 .312
Sleep 12 31 .674 12 34 .486 12 25 .546 0 34 .105 0 34 .132
Social 0 20 .029 0 22 .004 0 11 .153 0 0 1 0 11 .128
LASA
Symptoms 1 17 .005 8 16 .049 6 19 .258 7 8 .802 8 33 .044
Emotion 4 20 .001 6 15 .012 5 17 .093 4 13 .119 2 15 .259
Social 1 1 .265 1 9 .026 1 10 .030 0 5 .095 0 11 .124
Physical 6 28 .053 8 36 .012 4 17 .386 6 11 .686 4 11 .839
Qualitator
Symptoms 20 26 .052 24 27 .404 18 27 .228 21 25 .608 14 14 .692
Emotional 16 23 .309 16 20 .121 16 17 .860 14 21 .567 13 21 .160
Relations 7 10 .123 7 10 .035 7 9 .026 7 7 .054 7 11 .422
Physical 8 22 .024 11 20 .008 10 25 .003 10 21 .002 14 18 .247
weeks ofdiary completion were omitted by patients on inter-
mittent regimens who ran out of diaries during the treatment
delay due to neutropenic episodes.
Aaronson advocates that QoL measures should be capable
of disaggregation (Aaronson, 1988). This can be done with
the Qualitator but not as easily as with measures such as the
RSC, NHP and LASA. Besides, subscales may not neces-
sarily reflect the paramount concerns of the patient. In any
case it may be more appropriate to apply a specific instru-
ment to a specific area of interest (Ware, 1987).
In all trials where QoL is measured, the QoL of patients
who have left the study may continue to be affected by the
treatment they received, irrespective of response. By measur-
ing QoL only in patients still receiving treatment, a bias is
incurred which will tend to exclude non-responding patients,
who have a poorer QoL. This function ofstudy design rather
than instrument design may favour the use of an intermittent
QoL measure beyond the intended treatment period. For the
same reason, analyses of trend were not considered to offer
any greater accuracy of data interpretation than the simple346 S.C.A.FRASER et al.
analysis at each timepoint and comparison with initial scores.
Of the three instruments used in the Kings' study, the
Qualitator was easiest to administer as it was completed by
the patient at home. Data processing was time consuming for
all three, requiring entry on a computer spreadsheet, but
arrival at a global score quickest for the qualitator.
The Qualitator is not presented as the long-awaited gold-
standard and modification may be desirable with experience.
However, where simplicity of use and a single global QoL
score are desired, the Qualitator illustrates that collecting the
patient's chosen symptoms together and measuring the score
over time is feasible. When so few studies at present involve
QoL measurement, this may prove to be of singular value.
We are most grateful to Farmitalia Carlo Erba for the financial and
technical support which enabled the King's study to proceed, and the
Imperial Cancer Research Fund, which enabled the Guy's Study to
proceed. Qualitator diary cards may be obtained from Farmitalia
Carbo Erba, St Albans, Herts.
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